Growth funding Mainstay Medical has secured a substantial equity financing round of 125 million USD from Gilde Healthcare, signaling strong investor confidence and potential for scale in commercialization efforts and expansion into new markets.

Global expansion With subsidiaries in Ireland, the United States, Australia, Germany and the Netherlands and recent office expansions in Dublin, there are clear opportunities to partner on regional commercialization, reach key healthcare providers, and tailor sales strategies to regulatory environments across Europe and North America.

FDA approved therapy ReActiv8 is the first and only FDA-approved restorative treatment for mechanical chronic low back pain, presenting a defensible clinical value proposition and a strong differentiator for hospital systems, pain clinics and neuromodulation centers.

Clinical evidence momentum Ongoing and completed neuromodulation studies with long-term follow-up strengthen the case for broader adoption; sales teams can leverage study results to engage clinicians and payers, addressing efficacy, cost-benefit and patient outcomes.

Strategic leadership Key hires and board additions, including connections to Gilde’s US investments, indicate a proactive governance and fundraising posture, offering doors for strategic partnerships, co-marketing opportunities, and access to broader clinical and payer networks.